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1. Introduction
Biliary cancers are a heterogeneous group of highly malignant tu-
mors comprising the intrahepatic cholangiocarcinoma (ICCA), extra-
hepatic perihilar cholangiocarcinoma (PCCA), extrahepatic distal cho-
langiocarcinoma (DCCA) and gallbladder cancer (GBC) [1]. These
malignancies commonly share a dismal prognosis due to late diagnosis
and poor treatment options. The skeleton is the third site of metastasis
(following the liver and the lung) from solid tumors, especially lung
cancer, breast and prostate cancers. Studies carried out on this type of
tumors have shown that the presence of bone metastases may worsen
the prognosis and impair the patients’ quality of life [2–4]. However,
the possibility to offer different schedules of chemotherapy and the
improvement of supportive care have allowed an increase of life ex-
pectancy with a consequent increased risk to develop metastases in
uncommon site for the natural history of biliary tract cancers. In lit-
erature, data concerning the natural history of bone metastases from
biliary cancers are lacking: to our knowledge, this issue has been dis-
cussed only in small series or case reports and never investigated on a
large cohort of patients [5–8]. Therefore, we planned a multicenter
retrospective survey aiming to explore the prognostic impact of skeletal
involvement in patients with biliary cancers, evaluating clinical fea-
tures, incidence and type of skeletal related events and the potential
clinical impact of treatment with bisphosphonates.
2. Patients and methods
2.1. Ethic statement
The Ethics Committee of the coordination center approved this
multicenter observational study and determined that the written con-
sent was not necessary since all patients were dead at the time of the
survey. All methods are in accordance with relevant guidelines and
regulations.
2.2. Study design
This retrospective, observational study conducted in eleven Italian
cancer centers, enrolled 137 patients dead for biliary cancer with bone
metastases. The data collected related to patients of all ages with a
histological diagnosis of biliary cancer with bone metastases, treated in
the period from 2003 to 2014. At least two of the following criteria
were to be met to detect bone metastases: the presence reported by the
physician, the use of palliative bone radiotherapy and the recognition
of bone metastases by imaging tool (standard x-ray, computed tomo-
graphy scans or magnetic resonance imaging of the skeleton). All pa-
tients had received best treatment according to single center clinical
practice experience.
We excluded patients enrolled in clinical trials or dead for other
causes unrelated to cancer.
We collected data regarding clinical and epidemiological char-
acteristics, including age, specific cancer risk factors, histological type,
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site of cancer in biliary tree; number, sites, type and time of onset of
bone metastases; number, type and time of occurrence of skeletal re-
lated events (SREs); treatment with bisphosphonates or radiation
therapy; overall survival from biliary tract cancer diagnosis; overall
survival from bone metastasis diagnosis; time to first SRE.
We performed descriptive and survival analysis for each of these
parameters to identify their prognostic role.
2.3. Statistical analysis
Data were collected through descriptive statistics. The
Kaplan–Meier method was used to estimate the survival intervals.
Survival differences between specified groups were compared using the
log-rank test [9–10]. All the variables found to be significant in the
univariate model were considered for multivariate survival analysis and
assessed by application of the Cox proportional hazards model.
All significance levels were set at a 0.05 value. SPSS software
(version 19.00, SPSS, Chicago) was used for all statistical analysis.
Propensity score analysis was performed in R (v3.1.1) using nearest
neighbor matching with R package “MatchIt” .
3. Results
3.1. Patients and tumors characteristics
The median age of all patients was 64 years (34–84 years). Seventy-
three patients were men (53%), sixty-four women (47%). The most
frequent cancer was the ICCA (88 patients, 64%), followed by GBC (19
patients, 14%), ECCA (18 patients, 13%) and unknown site tumors (12
patients, 9%). Most patients had metastatic disease at diagnosis (94
patients, 68.6%); in the remaining cases the disease was diagnosed at
stage III in 12% of patients, stage II in 13% and 2% in I stage. 35% of
patients had bone metastases at the time of cancer diagnosis. The most
frequently used first-line regimens for metastatic disease were cisplatin
plus gemcitabine (24 patients, 17.5%), and gemcitabine plus oxaliplatin
(39 patients, 28.5%). Sixty-six patients (42%) were treated with other
chemotherapy regimens (48.2%) and only 8 patients (6%) received
supportive care alone due to poor clinical conditions or refusal. Eighty
patients underwent initial surgical treatment (58%), but only 35 of
them had no-residual surgery (R0). Eight patients (6%) received other
loco-regional treatments (thermoablation in 3 cases, chemoemboliza-
tion in 4 cases, yttrium-90 treatment in one case) [Table 1].
3.2. Bone metastases and skeletal related events
At the diagnosis of bone metastases, 36 patients had an Eastern
Cooperative Oncology Group Performance Status (ECOG PS) 0 (26.8%),
51 patients ECOG PS1 (37.6%), 35 patients ECOG PS 2 (25.5%), 13
patients ECOG PS 3 (9.5%) and one patient ECOG PS 4 (0.6%). Lytic
metastases occurred in 79 patients (57.5%), osteoblastic and mixed
lesions in 23 cases (17%) and in 28 cases (20.5%), respectively. At the
time of skeletal involvement, 26 patients had a single bone metastasis
(19%), 53 patients (39%) two or three metastases, 58 patients (42%)
more than three metastases. Only in seven cases (5%) the appearance of
bone metastasis preceded visceral metastases; in 35% of cases (48 pa-
tients) the diagnosis of bone metastases was synchronous with visceral
metastases and in 60% of cases (82 patients) was subsequent. The spine
was the most affected site (102 patients, 74.5%), followed by pelvic
bones (59 patients, 43%), long bones (43 patients, 31%) and other sites
(19 patients, 14%). Eighty-one patients did not develop any SRE (59%).
Among the 56 patients who experienced at least one SRE (41%), 19
patients of them had multiple SREs (sixteen patients had 2 SREs, three
patients had 3 SREs). The most common SRE was the need of radio-
therapy (44 cases, 58.6%), followed by fractures (12 cases, 16%), or-
thopedic surgery (9 cases, 12%), spinal compression (6 cases, 8%), and
hypercalcemia (4 cases, 5.4%). Sixty-seven patients (49%) were treated
with bisphosphonates, all but one with zoledronic acid [Table 2].
Thirty patients treated with bisphosphonates had at least one SRE
(45%), twelve of these had more than one SRE. Of the 70 patients who
were not treated with bisphosphonates, 27 (38%) had at least one SRE,
seven patients developed more than one SRE. In both groups, bone
metastases were predominantly osteolytic (in 41 cases in patients
Table 1
Descriptive analysis: patients and tumors characteristics.
Patients and tumors characteristics N° patients (%)
Risk factors
• No risk factor 69 (50.4)
• Alcoholic cirrhosis 6 (4.4)
• Biliary lithiasis 15 (11)
• Viral hepatitis 24 (17.6)
• Cholangitis 6 (4,4)
• Asbestos exposure 4 (3)
• Smoke 10 (7.3)
• Smoke and viral hepatitis 1 (0.7)
• Smoke and alcoholic cirrhosis 2 (1.4)
Primary site
• ICCA 88 (64)
• ECCA 18 (13)
• GBC 19 (14)
• Unknown site 12 (9)
First-line chemotherapy
• Cisplatin plus gemcitabine 24 (17.5)
• Oxaliplatin plus gemcitabine 39 (28,5)
• Others 66 (48)
• Unknown 8 (6)
Surgery
• No surgery 80 (58.4)
• R0 35 (25.5)
• R1 14 (10.2)
• R2 5 (3.6)
• Unknown 2 (2.3 )
Loco-regional treatments
• No treatments 128 (93.4)
• Thermo-ablation 3 (2,2)
• Chemoembolization 4 (3)
• Yttrium-90 1 (0.7)
Table 2
Descriptive analysis: bone metastases and skeletal related events.
Bone metastases and SREs N° patients (%)
Type
• Lytic 79 (57.5)
• Osteoblastic 23 (17)
• Mixed 28 (20)
• Unknown 7 (5)
Number of lesions
• 1 26 (19)
• 2–3 53 (39)
•>3 58 (42)
Site
• Spine 102 (74.5)
• Pelvic bones 59 (43)
• Long bones 43 (31)
• Other sites 19 (14)
Number of SRE
• 0 81 (59)
• At least 1 56(40)
• 2 16 (11.7)
• 3 3 (2,2)
SRE type
• Hypercalcemia 4 (5.4)
• Fractures 12 (16)
• Spinal compression 6 (8)
• Need of radiotherapy 44 (58.6)
• Orthopedic surgery 9 (12)
Bisphosphonates treatment
• Yes 67 (49)
• No 70 (51)
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treated with bisphosphonates and in 38 cases in untreated patients).
The need for radiotherapy is the first SRE in both groups (21 cases in
the group of patients treated with bisphosphonates and 23 in untreated
patients).
Table 3 displays the results obtained distinguishing the different
types of primitive biliary tumors (ICCA, ECCA, GBC). Number, type and
sites of bone metastases were similar across the three anatomic sub-
groups. The same applies to the number of SREs and type of the first
SRE.
3.3. Survival outcomes and time to first SRE
The median overall survival (OS) from biliary cancer diagnosis was
16.5 months (95%CI: 14.12–18.87). This outcome showed a statistically
significant correlation in univariate analysis with disease stage and
tumor site (p=0.001 and p=0.016, respectively). Patients with GBC
had shorter survival (10.9 months) compared to patients with ECCA or
ICCA (22.1 months and 16.3 months, respectively). In the multivariate
analysis, the primary tumor site lost its statistical significance, although
maintains a significance trend.
The median OS from bone metastases diagnosis in the whole po-
pulation was 6 months (95% CI: 4.9–7.1). Patients with a better ECOG
PS at the time of bone lesion diagnosis and treated with bispho-
sphonates had significantly longer OS. We recorded median OS (mOS)
ranging from 10.9 months in patients with ECOG PS 0 to 2 months in
patients with ECOG PS 3 (p=<0.001). Similarly, patients treated with
bisphosphonates had a longer mOS than those who were not exposed to
bisphosphonates: 8 months (95% CI: 6.26–9.74) versus 4 months (95%
CI: 3.00–4.99, p=0.001). This data was confirmed in multivariate
analysis (p=0.001) [Table 4, Fig. 1]. Radiological parameters such as
type, number and site of metastases did not shown any correlation with
the survival outcomes. The median time to first SRE by the diagnosis of
bone metastases in patients who experienced at least one SRE was 1.2
months (95% CI: 1.00–2.00). In patients treated with bisphosphonates,
the median time to first SRE is 2 months compared to 1 month in un-
treated patients (p=0,042; 95% Cl: 0.60–3.40).
After testing the proportional hazards assumption for a Cox
regression model fit we excluded ECOG PS as this variable did not sa-
tisfy the proportional hazards assumption [Supplementary Table A-B].
Cox regression analysis confirmed that Bisphosphonate treatment
was significantly associated with better prognosis in term of OS
[Table 5].
Table 3
Descriptive analysis: bone metastases and skeletal related events based on the
type of primary tumor.
Bone metastases and SREs N° events (%)
ICCA ECCA GBC
Type Bone Metastases
• Lytic 55 (62) 10 (11,5) 9 (13)
• Osteoblastic 14 (16) 3 (3,4) 4 (5,8)
• Mixed 16 (18) 5 (5,7) 5 (7,2)
• Unknown 3 (3,4) 0 1 (1,4)
Number of lesions
• 1 15 (17) 6 (7) 4 (5,8)
• 2–3 40 (45) 4 (4,6) 6 (8,7)
•>3 33 (37) 8 (9) 9 (13)
Site of metastases
• Spine 63 (71) 14 (16) 14 (20)
• Pelvic bones 34 (38) 7 (8) 10 (14,5)
• Long bones 27 (30) 5 (5,7) 8 (11,6)
• Other sites 11 (12) 4 (4,6) 3 (4,3)
Number of SRE
• 0 50 (56) 11 (12) 13 (19)
• 1 26 (30) 4 (4,6) 5 (7,2)
• 2 11 (12) 2 (2,3) 1 (1,4)
• 3 1 (1) 1 (1) 0
First SRE
• Hypercalcemia 4 (4,5) 0 0
• Fractures 6 (7) 1 (1,1) 1 (1,4)
• Spinal compression 3 (3,4) 0 1 (1,4)
• Need of radiotherapy 21 (24) 5 (5,7) 2 (3)
• Orthopedic surgery 3 (3,4) 1 (1) 0
Table 4
OS from diagnosis of bone metastases: univariate.
UNIVARIATE ANALYSIS
PARAMETER OS (months) P value 95% CI
ECOG PS
• 0 10.9 7,23 – 14,56
• 1 6 4,53 – 7,46
• 2 4 2,31 – 5,68




• Mixed 7 4,37 – 9,62
• Osteoblastic 5 2,78 – 7,21
• Osteolytic 5,3 3,17 – 7,42
0.762
NUMBER OF BONE METASTASES
• 1 5 3,44 – 6,56
• 2–3 7 4,88 – 9,11
•>3 6 3,70 – 8,29
0.810
SITES OF BONE METASTASES
• Axial 6 0.232 4,57 – 7,42
• Long bones 6,3 0.413 4,71 – 7,88
• Pelvic bones 7 0.373 4,89 – 9,10
• Other sites 6 0.579 2,72 – 9,27
VITAMIN D SUPPLEMENTATION
• Yes 10 5,78 – 14,21
• No 5,3 3,57 – 7,02
0.185
BONE METASTASES ONSET
• After visceral metastases 5,1 3,90 – 6,30
• Before visceral metastases 4 0,40 – 7,59
• Synchronous 6,3 4,06 – 8,53
0.950
BISPHOSPHONATES
• Yes 8 6,25 – 9,74
• No 4 3,00 – 4,99
0.001
AGE (yy)
•<64 4 0.118 2,850- 5,150
•>/=65 5.4 3,962 −6,838
Figure. 1. OS from bone metastases diagnosis in patients treated with bi-
sphosphonates or untreated. Kaplan-Meier survival analysis.
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4. Discussion
This is the first study that explored the natural history of bone
metastases in patients with biliary cancer, investigating multiple
parameters that may affect the onset of SRE and overall survival.
The Performance Status is the only parameter that significantly
correlates both with OS from diagnosis of bone metastases and with the
time to first SRE. It seems to be the most important prognostic factor:
bone metastatic biliary tract cancer patients with a PS ECOG>2
showed a significantly lower survival than those with better perfor-
mance status. Similarly, the PS appears to be a “frailty indicator” be-
cause patients with poor PS were at increased risk of developing SREs.
The descriptive analysis provided data never before achieved in such a
large number of patients: bone metastases from biliary cancers are more
frequently osteolytic (but osteoblastic ones are not a rare event) and
often associated with at least one SRE. The spine is the most involved
site and the need of radiotherapy is the most common SRE.
We believe that this study may contribute to increase our knowl-
edge on the prognostic impact of metastatic bone disease in biliary
cancers. In particular, the skeletal involvement seems to be associated
with a worse prognosis and a deterioration in quality of life. The high
percentage of cases with multiple lesions at the time of diagnosis of
bone metastases and the high number of patients with at least one SRE
(especially need of radiation therapy), suggests that most patients show
a low quality of life as well as a poor prognosis. In fact, although not
further investigated in our study, pain was the most common symptom.
Interestingly, the use of bisphosphonates was associated with longer
survival and significantly delayed the onset of the first SRE. At first
glance, these data seem to be vitiated by a selection bias, assuming that
only patients with good prognosis are treated with bisphosphonates. We
therefore considered four major clinical-pathological prognostic para-
meters both in patients treated with bisphosphonates than in those not
treated (ECOG PS, site of bone metastases, number of bone metastases,
bone metastases onset). Data obtained were similar in the two groups
[Table 6].
Anyway in a subsequent propensity score analysis, only presence of
metastases in other sites than axial skeleton, long bone and pelvic bones
demonstrated to have an influence on the decision to use bispho-
sphonate [Supplementary table C]. Although bisphosphonates’ treat-
ment is indicated in the presence of bone metastases regardless of the
skeletal sites involved, it is known that the involvement of other sites is
usually associated with a widespread skeletal involvement. In addition,
unusual bone metastases are often not susceptible to targeted treat-
ments such as radiotherapy.
Limitations of this study include its retrospective design and the
heterogeneity of the population under analysis (primary sites of biliary
cancer, multiple treatments considered).
Similar studies investigated the impact of bone metastases and bi-
sphosphonates in patients with solid tumors such as lung cancer, breast
cancer, prostate and gastrointestinal cancers. The presence of bone
metastases seems to be an independent predictor of poor prognosis.
Instead, the role of bisphosphonates is validated for many tumors, but
never adequately investigated in biliary cancers.
In lung cancer, bone metastases worsen the quality of life and ap-
pear to be associated with worse prognosis. The use of bisphosphonates
in these patients delay the first related skeletal event and appears to be
associated with an increase in survival [2]. For the same reasons, a rich
literature and major international guidelines sanction bisphosphonates
as a valid and useful support for patients with bone metastases from
breast or prostatic cancers [11–14]. Also in gastrointestinal and kidney
cancers, zoledronic acid treatment shown significant clinical benefit in
patients with bone metastases, although further investigations in these
populations of patients are warranted [15–18].
Likewise, our survey identified patients with biliary cancers as a
population whose prognosis and quality of life are deteriorated by
skeletal involvement and therefore susceptible to bisphosphonate
treatment.
This study has enhanced the knowledge about the natural history of
bone metastases in biliary cancers, providing some parameters that
correlate with survival and quality of life of the patients. These findings
may help the clinicians in clinical choices, but perspective studies are
needed to validate the survival impact of bisphosphonates.
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Table 5
OS from diagnosis of bone metastases: multivariate analysis.
P VALUE HR 95% C.I
LOWER UPPER
BISPHOSHONATE 0,006 0,506 0,312 0,821
BONE METASTASIS TYPE
Mixed 0,919 1,113 0,139 8,906
Osteoblastic 0,417 0,801 0,469 1,368
Osteolytic 0,634 0,870 0,491 1,541
NUMBER OF BONE METASTASES 0,842 0,929 0,452 1,911
SITES OF BONE METASTASES
Axial 0,152 1,478 0,864 2,528
Long bones 0,772 1,077 0,649 1,786
Pelvic bones 0,250 1,274 0,842 1,929
Other site 0,504 0,824 0,467 1,452
VITAMIN D SUPPLEMENTATION 0,746 0,907 0,502 1,636
BONE METASTASES ONSET (VS
SYNCHRONOUS)
After visceral metastases 0,345 1,229 0,801 1,885
Before visceral metastases 0,562 0,724 0,243 2,157
AGE 0,178 0,987 0,969 1,005
Table 6
Clinical and prognostic parameters in patients treated or not with bispho-
sphonates.
BISPHOSPHONATES TREATMENT
NO BPs (%) YES BPs (%)
ECOG PS
• 0 27,1 25,8
• 1 31,4 43,9
• 2 30 21,2
• 3–4 12,5 9,1
SITE PRIMARY CANCER
• ICCA 67 62,1
• ECCA 10 16,7
• GBC 12,9 15,2
• NA 10 6,1
BONE METASTASES ONSET
• After visceral metastases 58,6 62,1
• Before visceral metastases 5,7 4,5
• Synchronous 35,7 33,3
NUMBER BONE METASTASES
• 1 20 16,7
• 2–3 35,7 42,4
•>3 44,3 40,9
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Supplementary material associated with this article can be found, in
the online version, at doi:10.1016/j.jbo.2017.11.006.
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